Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Short Interest Up 39.3% in August

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 22,700 shares, a growth of 39.3% from the August 15th total of 16,300 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 149,200 shares, the short-interest ratio is presently 0.2 days.

In other Opiant Pharmaceuticals news, Director Craig A. Collard purchased 2,500 shares of the company’s stock in a transaction that occurred on Monday, September 13th. The stock was purchased at an average price of $18.13 per share, with a total value of $45,325.00. Following the completion of the transaction, the director now directly owns 16,077 shares of the company’s stock, valued at approximately $291,476.01. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael Sinclair sold 65,124 shares of the firm’s stock in a transaction that occurred on Monday, August 23rd. The stock was sold at an average price of $16.50, for a total transaction of $1,074,546.00. Following the sale, the director now directly owns 209,194 shares of the company’s stock, valued at approximately $3,451,701. The disclosure for this sale can be found here. Insiders have acquired 5,300 shares of company stock valued at $93,057 over the last 90 days. Corporate insiders own 28.56% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in OPNT. Wells Fargo & Company MN boosted its holdings in shares of Opiant Pharmaceuticals by 0.4% during the 2nd quarter. Wells Fargo & Company MN now owns 251,007 shares of the technology company’s stock worth $3,356,000 after buying an additional 925 shares during the period. Morgan Stanley boosted its holdings in shares of Opiant Pharmaceuticals by 11.8% during the 1st quarter. Morgan Stanley now owns 9,476 shares of the technology company’s stock worth $101,000 after buying an additional 1,000 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Opiant Pharmaceuticals by 11.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 21,831 shares of the technology company’s stock worth $232,000 after buying an additional 2,253 shares during the period. Apis Capital Advisors LLC boosted its holdings in shares of Opiant Pharmaceuticals by 5.0% during the 2nd quarter. Apis Capital Advisors LLC now owns 84,000 shares of the technology company’s stock worth $1,123,000 after buying an additional 4,000 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Opiant Pharmaceuticals by 17.6% during the 2nd quarter. Northern Trust Corp now owns 37,958 shares of the technology company’s stock worth $507,000 after buying an additional 5,668 shares during the period. 19.92% of the stock is owned by institutional investors.

OPNT stock traded up $0.48 during midday trading on Tuesday, hitting $24.50. The company’s stock had a trading volume of 1 shares, compared to its average volume of 77,305. The company has a debt-to-equity ratio of 0.52, a current ratio of 10.46 and a quick ratio of 10.46. Opiant Pharmaceuticals has a twelve month low of $6.79 and a twelve month high of $24.60. The company’s fifty day moving average price is $17.07 and its 200 day moving average price is $14.04. The stock has a market capitalization of $107.80 million, a P/E ratio of -66.72 and a beta of 0.75.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings results on Thursday, August 5th. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.59. Opiant Pharmaceuticals had a negative net margin of 3.06% and a negative return on equity of 3.17%. The firm had revenue of $11.26 million for the quarter, compared to analyst estimates of $8.01 million. Equities analysts expect that Opiant Pharmaceuticals will post -0.95 EPS for the current fiscal year.

OPNT has been the topic of several analyst reports. TheStreet upgraded shares of Opiant Pharmaceuticals from a “d” rating to a “c-” rating in a report on Wednesday, July 7th. Northland Securities initiated coverage on shares of Opiant Pharmaceuticals in a report on Wednesday, July 7th. They issued a “buy” rating and a $42.00 target price on the stock.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa.

Featured Article: Cash Flow Analysis in Stock Selection

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.